Eric Benevich serves as the Chief Commercial Officer at Neurocrine Biosciences, Inc., where he plays a pivotal role in steering the company's commercial strategy and operations. With a robust background in the biopharmaceutical industry, Benevich brings over two decades of experience to his position. Before joining Neurocrine Biosciences, he held significant roles at Shire, where he was instrumental in the successful launch and growth of several key products, including Vyvanse and Lialda. His leadership at Shire also involved overseeing the global commercial operations, which honed his skills in navigating complex markets and driving substantial revenue growth. At Neurocrine Biosciences, Benevich has been crucial in advancing the company's mission to develop treatments for neurological and endocrine-related disorders. Since taking on the role of Chief Commercial Officer, he has led the commercialization efforts for Ingrezza, a treatment for tardive dyskinesia and chorea associated with Huntington's disease, which has become a significant revenue driver for the company. Under his guidance, Neurocrine has expanded its commercial footprint and strengthened its market presence. Benevich's strategic vision and deep understanding of the biopharmaceutical landscape continue to be invaluable assets as Neurocrine Biosciences pursues its goal of bringing innovative therapies to patients in need.